TY - CPAPER
AU - Keir, Holly R.
AU - Long, Merete B
AU - Abo leyah, H.
AU - Giam, Yan Hui
AU - Vadiveloo, T.
AU - Pembridge, T.
AU - Hull, R.
AU - Delgado, Lilia
AU - Band, Margaret
AU - McLaren-Neil, Fiona
AU - Adamson, Simon
AU - Lahnsteiner, Eva
AU - Gilmour, A.
AU - Hughes, C.
AU - New, B. J. M.
AU - Connell, David
AU - Dowey, Rebecca
AU - Turton, H.
AU - Richardson, H.
AU - Cassidy, Diane
AU - Cooper, J.
AU - Suntharalingam, J.
AU - Diwakar, Lavanya
AU - Russell, P.
AU - Underwood, J.
AU - Hicks, Alexander
AU - Dosanjh, D.P.
AU - Sage, E.
AU - Dhasmana, Devesh
AU - Spears, M.
AU - Thompson, R.
AU - Brightling, Christopher E.
AU - Patel, M.
AU - George, J.
AU - Condliffe, Alison M.
AU - Shoemark, A.
AU - Maclennan, G.
AU - Chalmers, James D.
PY - 2022
DA - May
TI - A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial
DO - https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055
AB - Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count
PB - ATS journals
UR - https://discovery.dundee.ac.uk/en/publications/08025f36-4d21-4f9f-ae2b-5f1ce981e9e1
KW - Coronavirus (COVID-19)
KW - Hospital care
ER